These differences result in greater tumor penetration, bystander killing, and overall cytotoxicity with T-DXd, which translates into improved clinical outcomes, especially in patients with low HER2 expression or heterogeneous HER2+ tumors [45]. The gene discussed is ERBB2; the disease is neoplasm.